Relative to pharmacist administration of long-acting injectable drugs.
Impact
If enacted, SB250 would expand the scope of practice for pharmacists, which could lead to increased accessibility of medications for patients. This might particularly benefit those with chronic health conditions that require regular injections, as they could receive their medication from a pharmacist without the need for a physician visit. The act's provisions for pharmacist administration could potentially alleviate some of the burdens on healthcare systems by improving medication continuity.
Summary
Senate Bill 250 seeks to amend the state's regulations surrounding the administration of certain long-acting controlled drugs by allowing pharmacists to administer these drugs pursuant to a prescription. This change aims to streamline healthcare delivery, particularly in settings where patients may not have immediate access to a physician. By empowering pharmacists, the bill aspires to enhance patient care and improve medication adherence for chronic conditions requiring long-acting injectable medications.
Contention
Notably, discussions surrounding SB250 have raised questions about the appropriateness of expanding pharmacists' roles. Critics may voice concerns regarding the training and qualifications required for pharmacists to administer such medications safely and effectively. Additionally, there may be concern over patient safety, particularly related to the monitoring of effects following administration, which traditionally falls within the scope of physicians. These debates touch on broader themes of patient safety, professional roles in healthcare, and regulatory oversight.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.